Konstantinos Rokkas
Overview
Explore the profile of Konstantinos Rokkas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C
Nat Rev Cardiol
. 2021 Jul;
19(1):59-74.
PMID: 34331033
Sexual health has a fundamental role in overall health and well-being, and a healthy and dynamic sex life can make an important contribution to a good quality of life. Sexual...
2.
Vlachopoulos C, Ioakeimidis N, Rokkas K, Angelis A, Terentes-Printzios D, Kratiras Z, et al.
Am J Hypertens
. 2016 Dec;
30(3):249-255.
PMID: 27927629
Background: We investigated whether central hemodynamics predict major adverse cardiovascular events (MACEs) in erectile dysfunction (ED) patients beyond traditional risk factors. Methods: MACEs in relation to aortic pressures and augmentation...
3.
Ioakeimidis N, Vlachopoulos C, Rokkas K, Kratiras Z, Angelis A, Samentzas A, et al.
J Hypertens
. 2016 Apr;
34(5):860-8.
PMID: 27031932
Objective: Hypertension is associated with an abnormal penile blood flow. Reduced dynamic penile peak systolic velocity (D-PSV) correlates with adverse cardiovascular outcomes. The aim of this study is to investigate...
4.
Vlachopoulos C, Ioakeimidis N, Rokkas K, Angelis A, Terentes-Printzios D, Stefanadis C, et al.
Int J Cardiol
. 2015 Jan;
182:98-101.
PMID: 25577741
Background: Erectile dysfunction (ED) is associated with an incremental inflammatory activation. Evidence suggests that chronic phosphodiesterase 5 (PDE-5) inhibition may have a favorable effect on inflammatory activation and surrogate markers...
5.
Vlachopoulos C, Ioakeimidis N, Aznaouridis K, Terentes-Printzios D, Rokkas K, Aggelis A, et al.
Hypertension
. 2014 Jul;
64(3):672-8.
PMID: 24980671
Erectile dysfunction confers an independent risk for cardiovascular events and total mortality. Aortic pulse wave velocity (PWV) is an important predictor of cardiovascular events and all-cause mortality. We investigated whether...
6.
Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, Aznaouridis K, Rokkas K, Aggelis A, et al.
Am J Hypertens
. 2013 Feb;
26(3):373-81.
PMID: 23382488
Background: Androgen deficiency confers an independent risk for cardiovascular events and total mortality. Hypertension, a major contributory factor to the development of cardiovascular disease, has also been associated with increased...
7.
Vlachopoulos C, Terentes-Printzios D, Ioakeimidis N, Rokkas K, Samentzas A, Aggelis A, et al.
J Clin Pharmacol
. 2011 Sep;
52(8):1215-21.
PMID: 21953573
Although vardenafil is widely prescribed for erectile dysfunction (ED), its effect on arterial function is not defined. Aortic stiffness, aortic pressures, and wave reflections are predictors of cardiovascular risk. The...
8.
Ioakeimidis N, Vlachopoulos C, Rokkas K, Aggelis A, Terentes-Printzios D, Samentzas A, et al.
Eur Urol
. 2011 Feb;
59(6):948-55.
PMID: 21334135
Background: Asymmetric dimethylarginine (ADMA), a selective endogenous nitric oxide synthase inhibitor, is elevated in many conditions associated with erectile dysfunction (ED), such as hypertension, diabetes, hyperlipidemia, and renal failure; it...
9.
Deho F, Salonia A, Briganti A, Zanni G, Gallina A, Rokkas K, et al.
J Sex Med
. 2009 Feb;
6(2):578-83.
PMID: 19215620
Introduction: Only few reports addressed the outcome of patients submitted to anatomical radical retropubic prostatectomy (RRP) with an indwelling inflatable penile prosthesis (IPP). Aim: To assess the feasibility and safety...
10.
Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C
J Sex Med
. 2009 Jan;
6(3):658-74.
PMID: 19138362
Introduction: Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an increasing understanding of cyclic guanosine monophosphate (cGMP)-regulated...